These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1. Wang K; Tomaras GD; Jegaskanda S; Moody MA; Liao HX; Goodman KN; Berman PW; Rerks-Ngarm S; Pitisuttithum P; Nitayapan S; Kaewkungwal J; Haynes BF; Cohen JI J Virol; 2017 Oct; 91(19):. PubMed ID: 28701403 [TBL] [Abstract][Full Text] [Related]
5. Vaccine induced HSV 1 antibodies fail to correlate with protection against HSV 2 in guinea pigs. Welch MJ; Ridgeway PH; Phillpotts RJ FEMS Microbiol Immunol; 1988 Dec; 1(3):157-62. PubMed ID: 2856207 [TBL] [Abstract][Full Text] [Related]
6. The importance of MHC-I and MHC-II responses in vaccine efficacy against lethal herpes simplex virus type 1 challenge. Ghiasi H; Roopenian DC; Slanina S; Cai S; Nesburn AB; Wechsler SL Immunology; 1997 Jul; 91(3):430-5. PubMed ID: 9301533 [TBL] [Abstract][Full Text] [Related]
7. Immune responses to DNA free herpes simplex proteins in man. Cappel R; Sprecher S; de Cuyper F Dev Biol Stand; 1982; 52():345-50. PubMed ID: 6299843 [TBL] [Abstract][Full Text] [Related]
8. Animal studies on the efficacy of vaccination against recurrent herpes. Scriba M Med Microbiol Immunol; 1982; 171(1):33-42. PubMed ID: 6289061 [TBL] [Abstract][Full Text] [Related]
9. Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection. Mertz GJ; Ashley R; Burke RL; Benedetti J; Critchlow C; Jones CC; Corey L J Infect Dis; 1990 Apr; 161(4):653-60. PubMed ID: 2181031 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic periocular vaccination with a subunit vaccine induces higher levels of herpes simplex virus-specific tear secretory immunoglobulin A than systemic vaccination and provides protection against recurrent spontaneous ocular shedding of virus in latently infected rabbits. Nesburn AB; Burke RL; Ghiasi H; Slanina SM; Wechsler SL Virology; 1998 Dec; 252(1):200-9. PubMed ID: 9875329 [TBL] [Abstract][Full Text] [Related]
11. Preparation and efficacy of antiherpes type 1 and 2 subunit vaccines. Kavaklova L; Dundarov S; Andonov P; Bakalov B; Dundarova D; Brodvarova I Acta Virol; 1986 Sep; 30(5):402-10. PubMed ID: 2878588 [TBL] [Abstract][Full Text] [Related]
14. Placebo-controlled study with subunit herpes simplex virus vaccine in subjects suffering from frequent herpetic recurrences. Kutinová L; Benda R; Kalos Z; Dbalý V; Votruba T; Kvícalová E; Petrovská P; Doutlík S; Kamínková J; Domorázková E Vaccine; 1988 Jun; 6(3):223-8. PubMed ID: 2844031 [TBL] [Abstract][Full Text] [Related]
15. Antibody and cell-mediated immunity to a DNA free herpes simplex subunit vaccine. Cappel R; de Cuyper F; de Braekeleer J Dev Biol Stand; 1979; 43():381-5. PubMed ID: 230114 [TBL] [Abstract][Full Text] [Related]
16. Recombinant interleukin 2 as an adjuvant for vaccine-induced protection. Immunization of guinea pigs with herpes simplex virus subunit vaccines. Weinberg A; Merigan TC J Immunol; 1988 Jan; 140(1):294-9. PubMed ID: 2826591 [TBL] [Abstract][Full Text] [Related]